Samenvatting
Caspofungin, aechinocandin, is a relatively new lipophilic antifungal drug. Little is known concerning the pharmacokinetics of caspofungin in children. Extracorporeal membrane oxygenation (ECMO) allows prolonged cardiopulmonary support in patients with life-threatening respiratory or cardiac failure. Pharmacokinetics may be altered by ECMO. We describe the case of a paediatric patient on ECMO with severe pneumonia and sepsis, who had subtherapeutic exposure of caspofungin despite normal to high dosages of caspofungin. Therapeutic drug monitoring is warranted.
Originele taal-2 | Engels |
---|---|
Pagina's (van-tot) | 23-24 |
Aantal pagina's | 2 |
Tijdschrift | Medical Mycology Case Reports |
Volume | 2 |
Nummer van het tijdschrift | 1 |
DOI's | |
Status | Gepubliceerd - 2013 |
Extern gepubliceerd | Ja |